TITLE

Tuberculosis: clinical

PUB. DATE
December 2005
SOURCE
Thorax;Dec2005 Supplement 2, Vol. 60, pii18
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
The article presents abstracts related to medical research on tuberculosis. They include "Phase I/II Clinical of MVA85A in Individuals With Latent Tuberculosis: The First Subunit TB Vaccine in Clinical Trial," by C.R. Sander, A. Pathan, F. Gleeson, R.J.O. Davies, G. Pasvol, J. VanWijgerden, A.V.S. Hill, and H. McShane, "Prospective Study of Paradoxical Reactions in Tuberculosis Patients," by R.A.M. Breen, W. Holmes, F.Perrin, G. Bhatt, I. Cropley, M.A. Johnson and M.C.I. Lipman, and "MIRU-VNTR Fingerprinting of M tuberculosis Isolates From East Lancashire: 2001-05," by L.P. Ormerod, P. Maynard, I. Hafeez, D. Sails, and S. Barrett.
ACCESSION #
19836619

 

Related Articles

  • PhoP: A Missing Piece in the Intricate Puzzle of Mycobacterium tuberculosis Virulence. Gonzalo-Asensio, Jesús; Mostowy, Serge; Harders-Westerveen, Jose; Huygen, Kris; Hernández-Pando, Rogelio; Thole, Jelle; Behr, Marcel; Gicquel, Brigitte; Martín, Carlos // PLoS ONE;2008, Vol. 3 Issue 10, p1 

    Inactivation of the transcriptional regulator PhoP results in Mycobacterium tuberculosis attenuation. Preclinical testing has shown that attenuated M. tuberculosis phoP mutants hold promise as safe and effective live vaccine candidates. We focused this study to decipher the virulence networks...

  • The quest for a new vaccine against tuberculosis. Delogu, Giovanni; Fadda, Giovanni // Journal of Infection in Developing Countries;2009, Vol. 3 Issue 1, p5 

    Tuberculosis (TB) is still one of the deadliest human diseases, killing 1,6 million people each year, mostly in developing countries. The vaccine currently used, Bacille Calmette and Guerin (BCG), is effective in preventing the most severe disseminated forms of disease in children and newborns,...

  • New TB vaccines: is there a requirement for CD8+ T cells? W. Henry Boom // Journal of Clinical Investigation;Aug2007, Vol. 117 Issue 8, p2092 

    MHC class I-restricted CD8+ T cells are necessary to mount an immune response against Mycobacterium tuberculosis. M. tuberculosis antigens can enter MHC class I cross-processing pathways through a number of different mechanisms, including via the uptake of antigen-containing apoptotic vesicles...

  • Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines. Scriba, Thomas J.; Kaufmann, Stefan H. E.; Lambert, Paul Henri; Sanicas, Melvin; Martin, Carlos; Neyrolles, Olivier; Henri Lambert, Paul // Journal of Infectious Diseases;9/1/2016, Vol. 214 Issue 5, p659 

    Live attenuated and killed whole-cell vaccines (WCVs) offer promising vaccination strategies against tuberculosis. A number of WCV candidates, based on recombinant bacillus Calmette-Guerin (BCG), attenuated Mycobacterium tuberculosis, or related mycobacterial species are in various stages of...

  • Another Step Down the Development Pipeline for the Novel Tuberculosis Vaccine MVA-85A. Dockrell, Hazel M. // Journal of Infectious Diseases;6/15/2011, Vol. 203 Issue 12, p1708 

    In this article the author discusses development of the novel tuberculosis vaccine MVA-85A. The author says that infants had lower enzyme-linked immunosorbent spot (ELISPOT) responses to MVA85A than children aged 2-5 years, adolescents, or adults. The author further says that there were several...

  • Induced sputum or gastric lavage for community-based diagnosis of childhood pulmonary tuberculosis? Hatherill, M.; Hawkridge, T.; Zar, H. J.; Whitelaw, A.; Tameris, M.; Workman, L.; Geiter, L.; Hanekom1, W. A.; Hussey, G. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Mar2009, Vol. 94 Issue 3, p195 

    Objectives: To compare the diagnostic yield of Mycobacterium tuberculosis from induced sputum (IS) and gastric lavage (GL) among children in a community setting. Methods: Specimen-collection methods for bacteriological confirmation of pulmonary tuberculosis (PTB) were compared during a...

  • DNA vaccines against tuberculosis. Lowrie, Douglas B.; Silva, Cello L.; Tascon, Ricardo E. // Immunology & Cell Biology;Dec1997, Vol. 75 Issue 6, p591 

    This edited transcript of a presentation at the 'Vaccines Beyond 2000' conference describes a series of investigations by the authors throwing light on the mechanisms of protective immunity against tuberculosis in mice and raising hope for a new kind of vaccine to replace bacille...

  • Immunological requirements for a subunit vaccine against tuberculosis. Elhay, Martin J.; Andersen, Peter // Immunology & Cell Biology;Dec1997, Vol. 75 Issue 6, p595 

    Tuberculosis remains one of the most important threats to world health. Current vaccination and prevention strategies are inadequate and there is an urgent need for a new vaccine. The current vaccine bacille Calmette-Guerin (BCG). is unable to protect against re-activation of disease in later...

  • DNA vaccine for TB prevents recurrence. Bowden, Rachel // GP: General Practitioner;2/11/2005, p4 

    This article informs that a DNA vaccine for TB prevents recurrence of the disease in mice. Researchers infected four groups of mice with a low dose of Mycobacterium tuberculosis and treated them with the anti-tubercular agents isoniazid and pyrazinamide five times in the first four to 16 weeks...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics